Research progress of NF-κB signaling pathway in common diseases of thoracic surgery

doi:10.3877/cma.j.issn.2095-8773.2019.04.10

Abstract

Abstract:

Nuclear transcription factor Kappa B (NF-κB) is involved in a variety of signaling pathways, including inducing cell inhibition of apoptosis, promoting cell proliferation, invasion, metastasis, and promoting tumor cell angiogenesis, which are closely related to carcinogenesis. This review is intended to provide an overview of the progress in the study of NF-κB signaling pathways in non-small cell lung cancer and esophageal squamous cell carcinoma of common malignancies in thoracic surgery.

Key words: Nuclear transcription factor kappa B, Non-small cell lung cancer, Esophageal squamous cell carcinom

Baolei Liang, Hao Wei, Ke Shi, Changhai Shao, Xixian Ke, Qingyong Cai. Research progress of NF-κB signaling pathway in common diseases of thoracic surgery[J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2019, 06(04): 253-257.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbwkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8773.2019.04.10

https://zhxbwkdzzz.cma-cmc.com.cn/EN/Y2019/V06/I04/253

References 47

1	Struzik J, Szulc-Dabrowska L. NF-κB signaling in targeting tumor cells by oncolytic viruses—therapeutic perspectives [J]. Cancers, 2018, 10(11): E426.
2	Cui Z H, Xuan Y Z. Advances in the relationship between Nuclear factor-κB signal transduction pathway and tumor[J]. World Latest Medicne Information , 2015(21): 56-58.
3	Shujun Y, Jian L, Yu C, et al. MicroRNA-216a promotes M1 macrophages polarization and atherosclerosis progression by activating telomerase, via, the Smad3/NF-κB pathway[J]. Biochim Biophys Acta Mol Basis Dis, 2018, pii: S0925-4439(18)30220-30225.
4	李国仁，于世忠. 中国继发性食管癌的现状和进展[J]. 中华胸部外科电子杂志，2018, 5(1): 53-58.
5	Zhang Q, Lenardo M J, Baltimore D. 30 years of NF-κB: A blossoming of relevance to human pathobiology[J]. Cell, 2017, 168(1-2): 37-57.
6	Lehman H L, Kidacki M, Warrick J I, et al. NF-κB hyperactivation causes invasion of esophageal squamous cell carcinoma with EGFR overexpression and p120-catenin down-regulation [J]. Oncotarget, 2018, 9(13): 11180-11196.
7	Chen Z J. Ubiquitin signalling in the NF-κB pathway[J]．Nat Cell Biol，2005，7(8): 758-765.
8	Taniguchi K, Yamachika S, He F, et al. p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer[J]. Febs Letters, 2016, 590(15): 2375-2397.
9	Sun S C. The non-canonical NF-κB pathway in immunity and inflammation[J]. Nat Rev Immunol, 2017, 17(9): 545-558.
10	Slotta C, Schlüter T, Ruizperera L M, et al. CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle[J]. PLoS One, 2017, 12(8): e0182373.
11	Khan A, Fornes O, Stigliani A, et al. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework[J]. Nucleic Acids Res, 2017, 46(D1): D260-D266.
12	Bradford J W, Baldwin A S. IKK/nuclear factor-kappa B and oncogenesis: Roles in tumor-initiating cells and in the tumor microenvironment[J]. Adv Cancer Res, 2014，121: 125-145.
13	Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age[J]. Nat Rev Immunol, 2018, 22(2): 1-16.
14	Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018[J]. CA-Cancer J Clin, 2017, 67(1): 7-30.
15	Blakely C M, Pazarentzos E, Olivas V, et al. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer[J]. Cell rep, 2015, 11(1): 98-110.
16	Yang L, Zhou Y, Li Y，et al.Mutations of p53 and KRAS activate NF-κB to promote chemo resistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells[J]. Cancer Lett, 2015，357(2): 520-526.
17	王佳丽，张翔宇，邓佳，等. Bin1基因通过NF-κB途径抑制非小细胞肺癌A549细胞的迁移和侵袭能力[J]. 中国肿瘤生物治疗杂志，2016, 23(4): 481-485.
18	Yodkeeree S, Pompimon W, Limtrakul P．Crebanine，an aporphine alkaloid, sensitizes TNF-αinduced apoptosis and suppressed invasion of human lung adenocarcinoma cells A549 by blocking NF-κB regulated gene products[J]. Tumour Biol，2014，35(9): 8615-8624.
19	Gao P, Gao Y J, Liang H L．Effect of NF-κB inhibitor PDTC on VEGF and endostatin expression of mice with Lewis lung cancer[J]. Asian Pac J Trop Med，2015, 8(3): 220-224.
20	Zeng Q, Li S, Zhou Y，et al.Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression[J]．Cytokine，2014，65(1): 24-32.
21	Cheng X, Gu J, Zhang M，et al. Astragaloside Ⅳ inhibits migration and invasion in human lung cancer A549 cells via regulating PKC-α-ERK1/2-NF-κB pathway[J]. Int Immunopharmacol，2014，23(1): 304-313.
22	Kumar M, Allison D F, Baranova N N，et al.NF-κB regulates mesenchymal transition for the induction of non-small cell lung cancer initiating cells[J]．PLoS One，2013，8(7): e68597.
23	Slotta C, Storm J, Pfisterer N, et al. IKK1/2 protect human cells from TNF-mediated RIPK1-dependent apoptosis in an NF-κB-independent manner[J]. Biochim Biophys, 2018, 1865(8): 1025-1033.
24	Xia Y, Shen S, Verma I M. NF-κB, an active player in human cancers[J]. Cancer Immunol Res, 2014, 2(9): 823-830.
25	Xiao Z, Jiang Q, Willette-Brown J, et al. The pivotal role of IKKα in the development of spontaneous lung squamous cell carcinomas[J]. Cancer Cell, 2013, 23(4): 527-540.
26	Li N, Wu X, Holzer R G, et al. Loss of acinar cell IKKα triggers spontaneous pancreatitis in mice[J]. J Clin Investig, 2013, 123(5): 2231-2243.
27	Martin B N, Wang C, Willette-Brown J, et al. IKKα negatively regulates ASC-dependent inflammasome activation[J]. Nat Commun, 2014, 5(5): 4977.
28	Xiao D, Jia J, Shi Y, et al. Opposed expression of IKKα：Loss in keratinizing carcinomas and gain in non-keratinizing carcinomas[J]. Oncotarget, 2015, 6(28): 25499-25505.
29	Song N Y, Zhu F, Wang Z, et al. IKKα inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways[J]. Proc Natl Acad Sci, 2018, 115(4): E812-E821.
30	Grinberg-Bleyer Y, Oh H, Desrichard A, et al. NF-κB c-Rel is crucial for the regulatory T cell immune checkpoint in cancer[J]. Cell, 2017, 170(6): 1096-1108.
31	Lin C, Song L, Gong H，et al. Nkx2-8 down regulation promotes angiogenesis and activates NF-kappaB in esophageal cancer[J]. Cancer Res，2013，73(12): 3638-3648.
32	刘亮，贺红梅，左静，等. 食管上皮癌变过程中NF-κB与hTERT的表达及其意义[J]. 肿瘤防治研究，2014, 41(12): 1304-1306.
33	Cai Q Y, Liang G Y, Zheng Y F, et al. CCR7 enhances the angiogenic capacity of esophageal squamous carcinoma cells in vitro via activation of the NF-κB/VEGF signaling pathway[J]. Am J Transl Res, 2017, 9(7): 3282-3292.
34	Huang C Y, Lee C H, Tu C C, et al. Glucose-regulated protein 94 mediates progression and metastasis of esophageal squamous cell carcinoma via mitochondrial function and the NF-kB/COX-2/VEGF axis[J]. Oncotarget, 2018, 9(10): 9425-9441.
35	Ming X Y, Zhang X, Cao T T, et al. RHCG Suppresses Tumorigenicity and Metastasis in Esophageal Squamous Cell Carcinoma via Inhibiting NF-κB Signaling and MMP1 Expression[J]. Theranostics, 2018, 8(1): 185-198.
36	Mohammed S, Harikumar K B. Role of Nutraceuticals in Cancer Chemosensitization[M]//Bharti A C, Bhushan B．Cancer sensitizing agents for chemotherapy, 2018, 61-76.
37	Dimitrakopoulos F D, Antonacopoulou A G, Kottorou A E, et al. NF-κB2 genetic variations are significantly associated with non-small cell lung cancer risk and overall survival[J]. Sci Rep-UK, 2018, 8(1): 5259-5270.
38	Zhao Y, Foster N R, Meyers J P, et al. A phase Ⅰ/Ⅱ study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell Lung cancer: North central cancer treatment group (NCCTG)-N0321[J]. J Thorac Oncol, 2015, 10(1): 172-180.
39	Kontopodis E, Kotsakis A, Kentepozidis N, et al. A phase Ⅱ，open-label trial of bortezomib (VELCADE_®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer[J]. Cancer chemoth pharm, 2016, 77(5): 940-956.
40	Qu Y Q, Gordillo-Martinez F, Law B Y K, et al. 2-aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy[J]. Cell Death Dis, 2018, 9(3): 361-380.
41	Lu G, Middleton R E, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins[J]. Science, 2014, 343(6168): 305-309.
42	Würth R, Thellung S, Bajetto A, et al. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds[J]. Drug Discov Today, 2016, 21(1): 190-199.
43	König H G, Watters O, Kinsella S, et al. A constitutively-active IKK-complex at the axon initial segment[J]. Brain res, 2018, 1678: 356-366.
44	Lee K E, Hahm E, Bae S, et al. The enhanced tumor inhibitory effects of gefitinib and Lascorbic acid combination therapy in nonsmall cell lung cancer cells[J]. Oncol lett, 2017, 14(1): 276-282.
45	Tang H, Shrager J B. CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: a personalized molecular surgical therapy[J]. EMBO mol med, 2016, 8(2): 83-85.
46	Liu P, Wang Z, Brown S, et al. Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo[J]. Oncotarget, 2014, 5(17): 7471-7485.
47	Jivan R, Peres J, Damelin L H, et al. Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo[J]. Cancer lett, 2018, 417: 1-10.

[1]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[2]	Yiran Li, Yuxiu Wang, Yan Zhu, Meng Wang, Ying Liu, Wenjin Yan, Xingxiang Xu, Lingfeng Min. Analysis of differential genes that affect the efficacy of Nivolumab and Pembrolizumab in the treatment of non-small cell lung cancer based on GEO database [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 20-25.
[3]	Yuan Wang, Yi Yang, Yunfei Mou, Fuqiang Ren, Xin Huang. Analysis of postoperative osimertinib targeted therapy in patients with resectable non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(05): 657-660.
[4]	Ling Ma, Yinglong Li, Na Yue, Lifei Yang. Expression and clinical value of differential proteins in exosomes from non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(03): 327-330.
[5]	Xiaoqin Weng, Jiayang Qin, Yang Zhang, Jin Cui, Hong Shen. Effect of HIF-1α/VEGF-VEGFR2/Nrp-1 on Treg proliferation in NSCLC patients [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(06): 717-722.
[6]	Jie Ding, Xingxiang Liu, Xiaozhang Shen, Caixia Wang, Qing Guo. Efficacy of nano-albumin bound paclitaxel combined with cisplatin in treatment of esophageal squamous cell carcinoma [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(09): 892-896.
[7]	Jiu Yang, Mei Hong, Zhiyuan Liu, Nuo Zhu. Yiqi Chutan recipe combined with chemotherapy for treatment of patients with advanced non-small cell lung cancer: short-term curative effect and impact on serum levels of IL-2 and TNF-α and immune function [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(12): 948-953.
[8]	Bo Zhang, Bo Jin. Progress in research of Met as a target in non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 797-800.
[9]	Jingxiu Niu, Lihong Zhang, Hui Wang. Clinical study on the improvement of adverse reactions related to paclitaxel combined with cisplatin chemotherapy in advanced non-small cell lung cancer by grey screening method [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 774-778.
[10]	Kexin Tang, Xi Lin, Hong Shan. Doxorubicin-loaded fluorescent carbon dots with PEI passivation inhibited proliferation, migration and invasion of non-small cell lung cancer cells [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(02): 131-136.
[11]	Jiancong Feng, Ningli Chai, Enqiang Linghu. Application of digestive endoscopic super minimally invasive surgery in esophageal neoplastic diseases [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2022, 09(01): 45-50.
[12]	Shihao Li, Yujiao Wang, Zihao Li, Bin Wu, Yinliang Sheng, Yu Qi. Single cell transcriptome analysis of macrophage cap protein on proliferation and metastasis of esophageal squamous cell carcinoma cells [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2023, 10(02): 98-105.
[13]	Leilei Shen, Yang Liu. The staging evolution and treatment strategies of stage ⅠB non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(04): 246-254.
[14]	Xiao Liang, Lei Wang, Tao Jiang. Progress in surgical treatment of non-small cell lung cancer invading the chest wall [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 157-163.
[15]	Jianqiao Cai, Jing Huang, Lei Jiang. Double sleeve uniportal video-assisted thoracoscopic lobectomy—a retrospective study from shanghai pulmonary hospital [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 144-149.

Please choose a citation manager

Content to export